SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Medizone/OTC: MZEI (AIDS and Hepatitis B Treatment)
MZEI 0.00500-18.0%Oct 4 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Fred Carter who wrote (680)2/12/1999 8:03:00 AM
From: Power of 0  Read Replies (1) of 783
 
Thus, Medizone has 4 items to offer interested companies:

1. A patent that covers in vivo and ex vivo utilization of 02/03
mixtures. Ozone is defined as a drug and therefore is subject to all
applicable regulations. This patent covers the use of ozone as applied
to all biological systems, may they be a live patient, a member of the
mammalian family, or biological materials destined for human or
veterinary application.

2. Medizone has developed the technology to treat biological fluids with
a gaseous product (ozone/oxygen), with the utmost efficacy and accuracy.

3. Medizone has perfected medical ozone/oxygen delivery hardware, unique
on the market, capable of meeting all requirements imposed on drug
manufacture technology. It has the capability to tell a clinician the
exact dose of the drug being delivered. This system may be adapted or
modified to satisfy a variety of clinical and laboratory requisites (for
example, the purification and decontamination of large quantities of
biological materials).

4. Medizone has developed a patented peripheral delivery system insuring
accurate transfer of the 02/03 drug to its destination, be it a patient,
a mammal, or a biological substance. The thin film system is the only
one offering reliable and consistent gaseous drug delivery, thus
satisfying all the demands of rigorous laboratory and clinical
requirements.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News